Cardiology

Study authors sought to characterize the tolerance test, and HbA1c—in a population of patients with coronary artery disease (CAD).

I chronicled someone with type 1 diabetes whose ability to exercise was compromised by his use of statins back in April 2016. As you know, statins are a class of medications prescribed to lower cholesterol levels or abnormal levels of blood fats, with the goal being a reduction in the risk of heart attack and stroke. Brand name examples of statin medications include Altoprev, Crestor, Lescol, Lipitor, Livalo, Mevacor, Pravachol, and Zocor.

The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.

CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 1 of this ...

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 2 of this exclusive ...